Advertisement

2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary

      Abstract

      Arrhythmogenic cardiomyopathy (ACM) is an arrhythmogenic disorder of the myocardium not secondary to ischemic, hypertensive, or valvular heart disease. ACM incorporates a broad spectrum of genetic, systemic, infectious, and inflammatory disorders. This designation includes, but is not limited to, arrhythmogenic right/left ventricular cardiomyopathy, cardiac amyloidosis, sarcoidosis, Chagas disease, and left ventricular noncompaction. The ACM phenotype overlaps with other cardiomyopathies, particularly dilated cardiomyopathy with arrhythmia presentation that may be associated with ventricular dilatation and/or impaired systolic function. This expert consensus statement provides the clinician with guidance on evaluation and management of ACM and includes clinically relevant information on genetics and disease mechanisms. PICO questions were utilized to evaluate contemporary evidence and provide clinical guidance related to exercise in arrhythmogenic right ventricular cardiomyopathy. Recommendations were developed and approved by an expert writing group, after a systematic literature search with evidence tables, and discussion of their own clinical experience, to present the current knowledge in the field. Each recommendation is presented using the Class of Recommendation and Level of Evidence system formulated by the American College of Cardiology and the American Heart Association and is accompanied by references and explanatory text to provide essential context. The ongoing recognition of the genetic basis of ACM provides the opportunity to examine the diverse triggers and potential common pathway for the development of disease and arrhythmia.

      Keywords

      Abbreviations:

      ACE (angiotensin-converting enzyme), ACM (arrhythmogenic cardiomyopathy), ALVC (arrhythmogenic left ventricular cardiomyopathy), ARB (angiotensin receptor blocker), ARVC (arrhythmogenic right ventricular cardiomyopathy), AV (atrioventricular), CMR (cardiac magnetic resonance imaging), COR (Class of Recommendation), DCM (dilated cardiomyopathy), ECG (electrocardiogram), EPS (electrophysiology study), ICD (implantable cardioverter defibrillator), LOE (Level of Evidence), LV (left ventricle), LVNC (left ventricular noncompaction), MET (metabolic equivalent), NSVT (nonsustained ventricular tachycardia), NYHA (New York Heart Association), PVC (premature ventricular contraction), RV (right ventricle), VF (ventricular fibrillation), VT (ventricular tachycardia)
      To read this article in full you will need to make a payment
      Subscribe to Heart Rhythm
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Indik J.H.
        • Patton K.K.
        • Beardsall M.
        • et al.
        HRS Clinical Document Development Methodology Manual and Policies: Executive summary.
        Heart Rhythm. 2017; 14: e495-e500
        • Halperin J.L.
        • Levine G.N.
        • Al-Khatib S.M.
        • et al.
        Further Evolution of the ACC/AHA Clinical Practice Guideline Recommendation Classification System: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
        Circulation. 2016; 133: 1426-1428
        • Al-Khatib S.M.
        • Stevenson W.G.
        • Ackerman M.J.
        • et al.
        2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.
        Heart Rhythm. 2018; 15: e73-e189
        • Epstein A.E.
        • DiMarco J.P.
        • Ellenbogen K.A.
        • et al.
        ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities.
        Heart Rhythm. 2008; 5: e1-e62
        • Ackerman M.J.
        • Priori S.G.
        • Willems S.
        • et al.
        HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies.
        Heart Rhythm. 2011; 8: 1308-1339
        • Priori S.G.
        • Wilde A.A.
        • Horie M.
        • et al.
        HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes.
        Heart Rhythm. 2013; 10: 1932-1963
        • Yancy C.W.
        • Jessup M.
        • Bozkurt B.
        • et al.
        2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.
        J Am Coll Cardiol. 2016; 68: 1476-1488
        • Yancy C.W.
        • Jessup M.
        • Bozkurt B.
        • et al.
        2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2013; 62: e147-e239
        • Ponikowski P.
        • Voors A.A.
        • Anker S.D.
        • et al.
        2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
        Eur Heart J. 2016; 37: 2129-2200
        • Marcus F.I.
        • McKenna W.J.
        • Sherrill D.
        • et al.
        Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria.
        Circulation. 2010; 121: 1533-1541
        • Hershberger R.E.
        • Givertz M.M.
        • Ho C.Y.
        • Judge D.P.
        • Kantor P.F.
        • McBride K.L.
        • Morales A.
        • Taylor M.R.G.
        • Vatta M.
        • Ware S.M.
        Genetic Evaluation of Cardiomyopathy-A Heart Failure Society of America Practice Guideline.
        J Card Fail. 2018; 24: 281-302
        • Corrado D.
        • Wichter T.
        • Link M.S.
        • et al.
        Treatment of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: An International Task Force Consensus Statement.
        Circulation. 2015; 132: 441-453
        • Hoshijima M.
        Mechanical stress-strain sensors embedded in cardiac cytoskeleton: Z disk, titin, and associated structures.
        Am J Physiol Heart Circ Physiol. 2006; 290: H1313-H1325
        • Cox M.G.
        • van der Smagt J.J.
        • Noorman M.
        • et al.
        Arrhythmogenic right ventricular dysplasia/cardiomyopathy diagnostic task force criteria: impact of new task force criteria.
        Circ Arrhythm Electrophysiol. 2010; 3: 126-133
        • Nunes de Alencar Neto J.
        • Baranchuk A.
        • Bayes-Genis A.
        • Bayes de Luna A.
        Arrhythmogenic right ventricular dysplasia/cardiomyopathy: an electrocardiogram-based review.
        Europace. 2018; 20: f3-f12
        • Plon S.E.
        • Eccles D.M.
        • Easton D.
        • Foulkes W.D.
        • Genuardi M.
        • Greenblatt M.S.
        • Hogervorst F.B.
        • Hoogerbrugge N.
        • Spurdle A.B.
        • Tavtigian S.V.
        Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results.
        Hum Mutat. 2008; 29: 1282-1291
        • Walsh R.
        • Thomson K.L.
        • Ware J.S.
        • et al.
        Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples.
        Genet Med. 2017; 19: 192-203
        • Bienengraeber M.
        • Olson T.M.
        • Selivanov V.A.
        • et al.
        ABCC9 mutations identified in human dilated cardiomyopathy disrupt catalytic KATP channel gating.
        Nat Genet. 2004; 36: 382-387
        • Rampazzo A.
        • Nava A.
        • Malacrida S.
        • Beffagna G.
        • Bauce B.
        • Rossi V.
        • Zimbello R.
        • Simionati B.
        • Basso C.
        • Thiene G.
        • Towbin J.A.
        • Danieli G.A.
        Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy.
        Am J Hum Genet. 2002; 71: 1200-1206
        • Taylor M.
        • Graw S.
        • Sinagra G.
        • et al.
        Genetic variation in titin in arrhythmogenic right ventricular cardiomyopathy-overlap syndromes.
        Circulation. 2011; 124: 876-885
        • van Hengel J.
        • Calore M.
        • Bauce B.
        • et al.
        Mutations in the area composita protein alphaT-catenin are associated with arrhythmogenic right ventricular cardiomyopathy.
        Eur Heart J. 2013; 34: 201-210
        • Murray B.
        • Hoorntje E.T.
        • Te Riele A.
        • et al.
        Identification of sarcomeric variants in probands with a clinical diagnosis of arrhythmogenic right ventricular cardiomyopathy (ARVC).
        J Cardiovasc Electrophysiol. 2018; 29: 1004-1009
        • Medeiros-Domingo A.
        • Saguner A.M.
        • Magyar I.
        • Bahr A.
        • Akdis D.
        • Brunckhorst C.
        • Duru F.
        • Berger W.
        Arrhythmogenic right ventricular cardiomyopathy: implications of next-generation sequencing in appropriate diagnosis.
        Europace. 2017; 19: 1063-1069
        • Mayosi B.M.
        • Fish M.
        • Shaboodien G.
        • et al.
        Identification of Cadherin 2 (CDH2) Mutations in Arrhythmogenic Right Ventricular Cardiomyopathy.
        Circ Cardiovasc Genet. 2017; 10
        • Turkowski K.L.
        • Tester D.J.
        • Bos J.M.
        • Haugaa K.H.
        • Ackerman M.J.
        Whole exome sequencing with genomic triangulation implicates CDH2-encoded N-cadherin as a novel pathogenic substrate for arrhythmogenic cardiomyopathy.
        Congenit Heart Dis. 2017; 12: 226-235
        • De Bortoli M.
        • Postma A.V.
        • Poloni G.
        • et al.
        Whole-Exome Sequencing Identifies Pathogenic Variants in TJP1 Gene Associated With Arrhythmogenic Cardiomyopathy.
        Circ Genom Precis Med. 2018; 11: e002123
        • Kapplinger J.D.
        • Landstrom A.P.
        • Salisbury B.A.
        • et al.
        Distinguishing arrhythmogenic right ventricular cardiomyopathy/dysplasia-associated mutations from background genetic noise.
        J Am Coll Cardiol. 2011; 57: 2317-2327
        • Norton N.
        • Li D.
        • Rieder M.J.
        • et al.
        Genome-wide studies of copy number variation and exome sequencing identify rare variants in BAG3 as a cause of dilated cardiomyopathy.
        Am J Hum Genet. 2011; 88: 273-282
        • Hedberg C.
        • Melberg A.
        • Kuhl A.
        • Jenne D.
        • Oldfors A.
        Autosomal dominant myofibrillar myopathy with arrhythmogenic right ventricular cardiomyopathy 7 is caused by a DES mutation.
        Eur J Hum Genet. 2012; 20: 984-985
        • Syrris P.
        • Ward D.
        • Evans A.
        • Asimaki A.
        • Gandjbakhch E.
        • Sen-Chowdhry S.
        • McKenna W.J.
        Arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in the desmosomal gene desmocollin-2.
        Am J Hum Genet. 2006; 79: 978-984
        • Awad M.M.
        • Dalal D.
        • Cho E.
        • Amat-Alarcon N.
        • James C.
        • Tichnell C.
        • Tucker A.
        • Russell S.D.
        • Bluemke D.A.
        • Dietz H.C.
        • Calkins H.
        • Judge D.P.
        DSG2 mutations contribute to arrhythmogenic right ventricular dysplasia/cardiomyopathy.
        Am J Hum Genet. 2006; 79: 136-142
        • Yang Z.
        • Bowles N.E.
        • Scherer S.E.
        • et al.
        Desmosomal dysfunction due to mutations in desmoplakin causes arrhythmogenic right ventricular dysplasia/cardiomyopathy.
        Circ Res. 2006; 99: 646-655
        • Norgett E.E.
        • Hatsell S.J.
        • Carvajal-Huerta L.
        • Cabezas J.C.
        • Common J.
        • Purkis P.E.
        • Whittock N.
        • Leigh I.M.
        • Stevens H.P.
        • Kelsell D.P.
        Recessive mutation in desmoplakin disrupts desmoplakin-intermediate filament interactions and causes dilated cardiomyopathy, woolly hair and keratoderma.
        Hum Mol Genet. 2000; 9: 2761-2766
        • Ortiz-Genga M.F.
        • Cuenca S.
        • Dal Ferro M.
        • et al.
        Truncating FLNC mutations are associated with high-risk dilated and arrhythmogenic cardiomyopathies.
        J Am Coll Cardiol. 2016; 68: 2440-2451
        • Asimaki A.
        • Syrris P.
        • Wichter T.
        • Matthias P.
        • Saffitz J.E.
        • McKenna W.J.
        A novel dominant mutation in plakoglobin causes arrhythmogenic right ventricular cardiomyopathy.
        Am J Hum Genet. 2007; 81: 964-973
        • McKoy G.
        • Protonotarios N.
        • Crosby A.
        • Tsatsopoulou A.
        • Anastasakis A.
        • Coonar A.
        • Norman M.
        • Baboonian C.
        • Jeffery S.
        • McKenna W.J.
        Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease).
        Lancet. 2000; 355: 2119-2124
        • Vatta M.
        • Mohapatra B.
        • Jimenez S.
        • et al.
        Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction.
        J Am Coll Cardiol. 2003; 42: 2014-2027
        • Quarta G.
        • Syrris P.
        • Ashworth M.
        • Jenkins S.
        • Zuborne Alapi K.
        • Morgan J.
        • Muir A.
        • Pantazis A.
        • McKenna W.J.
        • Elliott P.M.
        Mutations in the Lamin A/C gene mimic arrhythmogenic right ventricular cardiomyopathy.
        Eur Heart J. 2012; 33: 1128-1136
        • Pashmforoush M.
        • Lu J.T.
        • Chen H.
        • et al.
        Nkx2-5 pathways and congenital heart disease; loss of ventricular myocyte lineage specification leads to progressive cardiomyopathy and complete heart block.
        Cell. 2004; 117: 373-386
        • Gerull B.
        • Heuser A.
        • Wichter T.
        • et al.
        Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy.
        Nat Genet. 2004; 36: 1162-1164
        • Schmitt J.P.
        • Kamisago M.
        • Asahi M.
        • Li G.H.
        • Ahmad F.
        • Mende U.
        • Kranias E.G.
        • MacLennan D.H.
        • Seidman J.G.
        • Seidman C.E.
        Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban.
        Science. 2003; 299: 1410-1413
        • van der Zwaag P.A.
        • van Rijsingen I.A.
        • Asimaki A.
        • et al.
        Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy.
        Eur J Heart Fail. 2012; 14: 1199-1207
        • Brauch K.M.
        • Karst M.L.
        • Herron K.J.
        • de Andrade M.
        • Pellikka P.A.
        • Rodeheffer R.J.
        • Michels V.V.
        • Olson T.M.
        Mutations in ribonucleic acid binding protein gene cause familial dilated cardiomyopathy.
        J Am Coll Cardiol. 2009; 54: 930-941
        • McNair W.P.
        • Ku L.
        • Taylor M.R.
        • Fain P.R.
        • Dao D.
        • Wolfel E.
        • Mestroni L.
        • Familial Cardiomyopathy Registry Research G
        SCN5A mutation associated with dilated cardiomyopathy, conduction disorder, and arrhythmia.
        Circulation. 2004; 110: 2163-2167
        • Merner N.D.
        • Hodgkinson K.A.
        • Haywood A.F.
        • et al.
        Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in the TMEM43 gene.
        Am J Hum Genet. 2008; 82: 809-821
        • Quarta G.
        • Muir A.
        • Pantazis A.
        • Syrris P.
        • Gehmlich K.
        • Garcia-Pavia P.
        • Ward D.
        • Sen-Chowdhry S.
        • Elliott P.M.
        • McKenna W.J.
        Familial evaluation in arrhythmogenic right ventricular cardiomyopathy: impact of genetics and revised task force criteria.
        Circulation. 2011; 123: 2701-2709
        • Hodgkinson K.A.
        • Connors S.P.
        • Merner N.
        • Haywood A.
        • Young T.L.
        • McKenna W.J.
        • Gallagher B.
        • Curtis F.
        • Bassett A.S.
        • Parfrey P.S.
        The natural history of a genetic subtype of arrhythmogenic right ventricular cardiomyopathy caused by a p.S358L mutation in TMEM43.
        Clin Genet. 2013; 83: 321-331
        • van Tintelen J.P.
        • Van Gelder I.C.
        • Asimaki A.
        • et al.
        Severe cardiac phenotype with right ventricular predominance in a large cohort of patients with a single missense mutation in the DES gene.
        Heart Rhythm. 2009; 6: 1574-1583
        • Hasselberg N.E.
        • Haland T.F.
        • Saberniak J.
        • Brekke P.H.
        • Berge K.E.
        • Leren T.P.
        • Edvardsen T.
        • Haugaa K.H.
        Lamin A/C cardiomyopathy: young onset, high penetrance, and frequent need for heart transplantation.
        Eur Heart J. 2018; 39: 853-860
        • van Rijsingen I.A.
        • van der Zwaag P.A.
        • Groeneweg J.A.
        • et al.
        Outcome in phospholamban R14del carriers: results of a large multicentre cohort study.
        Circ Cardiovasc Genet. 2014; 7: 455-465
        • Te Riele A.S.
        • James C.A.
        • Groeneweg J.A.
        • et al.
        Approach to family screening in arrhythmogenic right ventricular dysplasia/cardiomyopathy.
        Eur Heart J. 2016; 37: 755-763
        • Bauce B.
        • Rampazzo A.
        • Basso C.
        • et al.
        Clinical phenotype and diagnosis of arrhythmogenic right ventricular cardiomyopathy in pediatric patients carrying desmosomal gene mutations.
        Heart Rhythm. 2011; 8: 1686-1695
        • Groeneweg J.A.
        • Bhonsale A.
        • James C.A.
        • et al.
        Clinical Presentation, Long-Term Follow-Up, and Outcomes of 1001 Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Patients and Family Members.
        Circ Cardiovasc Genet. 2015; 8: 437-446
        • Dalal D.
        • James C.
        • Devanagondi R.
        • Tichnell C.
        • Tucker A.
        • Prakasa K.
        • Spevak P.J.
        • Bluemke D.A.
        • Abraham T.
        • Russell S.D.
        • Calkins H.
        • Judge D.P.
        Penetrance of mutations in plakophilin-2 among families with arrhythmogenic right ventricular dysplasia/cardiomyopathy.
        J Am Coll Cardiol. 2006; 48: 1416-1424
        • Hamid M.S.
        • Norman M.
        • Quraishi A.
        • Firoozi S.
        • Thaman R.
        • Gimeno J.R.
        • Sachdev B.
        • Rowland E.
        • Elliott P.M.
        • McKenna W.J.
        Prospective evaluation of relatives for familial arrhythmogenic right ventricular cardiomyopathy/dysplasia reveals a need to broaden diagnostic criteria.
        J Am Coll Cardiol. 2002; 40: 1445-1450
        • te Riele A.S.
        • James C.A.
        • Rastegar N.
        • Bhonsale A.
        • Murray B.
        • Tichnell C.
        • Judge D.P.
        • Bluemke D.A.
        • Zimmerman S.L.
        • Kamel I.R.
        • Calkins H.
        • Tandri H.
        Yield of serial evaluation in at-risk family members of patients with ARVD/C.
        J Am Coll Cardiol. 2014; 64: 293-301
        • Protonotarios A.
        • Anastasakis A.
        • Panagiotakos D.B.
        • Antoniades L.
        • Syrris P.
        • Vouliotis A.
        • Stefanadis C.
        • Tsatsopoulou A.
        • McKenna W.J.
        • Protonotarios N.
        Arrhythmic risk assessment in genotyped families with arrhythmogenic right ventricular cardiomyopathy.
        Europace. 2016; 18: 610-616
        • Perrin M.J.
        • Angaran P.
        • Laksman Z.
        • Zhang H.
        • Porepa L.F.
        • Rutberg J.
        • James C.
        • Krahn A.D.
        • Judge D.P.
        • Calkins H.
        • Gollob M.H.
        Exercise testing in asymptomatic gene carriers exposes a latent electrical substrate of arrhythmogenic right ventricular cardiomyopathy.
        J Am Coll Cardiol. 2013; 62: 1772-1779
        • Corrado D.
        • Leoni L.
        • Link M.S.
        • et al.
        Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia.
        Circulation. 2003; 108: 3084-3091
        • Hulot J.S.
        • Jouven X.
        • Empana J.P.
        • Frank R.
        • Fontaine G.
        Natural history and risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy.
        Circulation. 2004; 110: 1879-1884
        • Link M.S.
        • Laidlaw D.
        • Polonsky B.
        • Zareba W.
        • McNitt S.
        • Gear K.
        • Marcus F.
        • Estes 3rd, N.A.
        Ventricular arrhythmias in the North American multidisciplinary study of ARVC: predictors, characteristics, and treatment.
        J Am Coll Cardiol. 2014; 64: 119-125
        • Orgeron G.M.
        • James C.A.
        • Te Riele A.
        • Tichnell C.
        • Murray B.
        • Bhonsale A.
        • Kamel I.R.
        • Zimmerman S.L.
        • Judge D.P.
        • Crosson J.
        • Tandri H.
        • Calkins H.
        Implantable Cardioverter-Defibrillator Therapy in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Predictors of Appropriate Therapy, Outcomes, and Complications.
        J Am Heart Assoc. 2017; 6
        • Hodgkinson K.A.
        • Parfrey P.S.
        • Bassett A.S.
        • Kupprion C.
        • Drenckhahn J.
        • Norman M.W.
        • Thierfelder L.
        • Stuckless S.N.
        • Dicks E.L.
        • McKenna W.J.
        • Connors S.P.
        The impact of implantable cardioverter-defibrillator therapy on survival in autosomal-dominant arrhythmogenic right ventricular cardiomyopathy (ARVD5).
        J Am Coll Cardiol. 2005; 45: 400-408
        • Bardy G.H.
        • Lee K.L.
        • Mark D.B.
        • et al.
        Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
        N Engl J Med. 2005; 352: 225-237
        • van Rijsingen I.A.
        • Arbustini E.
        • Elliott P.M.
        • et al.
        Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study.
        J Am Coll Cardiol. 2012; 59: 493-500
        • Bansch D.
        • Antz M.
        • Boczor S.
        • Volkmer M.
        • Tebbenjohanns J.
        • Seidl K.
        • Block M.
        • Gietzen F.
        • Berger J.
        • Kuck K.H.
        Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT).
        Circulation. 2002; 105: 1453-1458
        • Bristow M.R.
        • Saxon L.A.
        • Boehmer J.
        • et al.
        Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
        N Engl J Med. 2004; 350: 2140-2150
        • Desai A.S.
        • Fang J.C.
        • Maisel W.H.
        • Baughman K.L.
        Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials.
        JAMA. 2004; 292: 2874-2879
        • Kadish A.
        • Dyer A.
        • Daubert J.P.
        • et al.
        Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy.
        N Engl J Med. 2004; 350: 2151-2158
        • Strickberger S.A.
        • Hummel J.D.
        • Bartlett T.G.
        • Frumin H.I.
        • Schuger C.D.
        • Beau S.L.
        • Bitar C.
        • Morady F.
        • Investigators A.
        Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia--AMIOVIRT.
        J Am Coll Cardiol. 2003; 41: 1707-1712
        • Corrado D.
        • Calkins H.
        • Link M.S.
        • et al.
        Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia.
        Circulation. 2010; 122: 1144-1152
        • Mazzanti A.
        • Ng K.
        • Faragli A.
        • et al.
        Arrhythmogenic Right Ventricular Cardiomyopathy: Clinical Course and Predictors of Arrhythmic Risk.
        J Am Coll Cardiol. 2016; 68: 2540-2550
        • Pinamonti B.
        • Dragos A.M.
        • Pyxaras S.A.
        • Merlo M.
        • Pivetta A.
        • Barbati G.
        • Di Lenarda A.
        • Morgera T.
        • Mestroni L.
        • Sinagra G.
        Prognostic predictors in arrhythmogenic right ventricular cardiomyopathy: results from a 10-year registry.
        Eur Heart J. 2011; 32: 1105-1113
        • Anselme F.
        • Moubarak G.
        • Savoure A.
        • Godin B.
        • Borz B.
        • Drouin-Garraud V.
        • Gay A.
        Implantable cardioverter-defibrillators in lamin A/C mutation carriers with cardiac conduction disorders.
        Heart Rhythm. 2013; 10: 1492-1498
        • Kimura Y.
        • Noda T.
        • Otsuka Y.
        • et al.
        Potentially Lethal Ventricular Arrhythmias and Heart Failure in Arrhythmogenic Right Ventricular Cardiomyopathy: What Are the Differences Between Men and Women?.
        JACC Clin Electrophysiol. 2016; 2: 546-555
        • Pasotti M.
        • Klersy C.
        • Pilotto A.
        • et al.
        Long-term outcome and risk stratification in dilated cardiolaminopathies.
        J Am Coll Cardiol. 2008; 52: 1250-1260
        • Wlodarska E.K.
        • Wozniak O.
        • Konka M.
        • Rydlewska-Sadowska W.
        • Biederman A.
        • Hoffman P.
        Thromboembolic complications in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy.
        Europace. 2006; 8: 596-600
        • Ruwald M.H.
        • Abu-Zeitone A.
        • Jons C.
        • Ruwald A.C.
        • McNitt S.
        • Kutyifa V.
        • Zareba W.
        • Moss A.J.
        Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy).
        J Am Coll Cardiol. 2013; 62: 1343-1350
        • Marcus G.M.
        • Glidden D.V.
        • Polonsky B.
        • Zareba W.
        • Smith L.M.
        • Cannom D.S.
        • Estes 3rd, N.A.
        • Marcus F.
        • Scheinman M.M.
        Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry.
        J Am Coll Cardiol. 2009; 54: 609-615
        • Connolly S.J.
        • Dorian P.
        • Roberts R.S.
        • Gent M.
        • Bailin S.
        • Fain E.S.
        • Thorpe K.
        • Champagne J.
        • Talajic M.
        • Coutu B.
        • Gronefeld G.C.
        • Hohnloser S.H.
        Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
        Jama. 2006; 295: 165-171
        • Ermakov S.
        • Gerstenfeld E.P.
        • Svetlichnaya Y.
        • Scheinman M.M.
        Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy.
        Heart Rhythm. 2017; 14: 564-569
        • Tokuda M.
        • Tedrow U.B.
        • Kojodjojo P.
        • Inada K.
        • Koplan B.A.
        • Michaud G.F.
        • John R.M.
        • Epstein L.M.
        • Stevenson W.G.
        Catheter ablation of ventricular tachycardia in nonischemic heart disease.
        Circ Arrhythm Electrophysiol. 2012; 5: 992-1000
        • Sapp J.L.
        • Wells G.A.
        • Parkash R.
        • et al.
        Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
        N Engl J Med. 2016; 375: 111-121
        • Tung R.
        • Vaseghi M.
        • Frankel D.S.
        • et al.
        Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease: An International VT Ablation Center Collaborative Group study.
        Heart Rhythm. 2015; 12: 1997-2007
        • Tzou W.S.
        • Tung R.
        • Frankel D.S.
        • et al.
        Outcomes after repeat ablation of ventricular tachycardia in structural heart disease: An analysis from the International VT Ablation Center Collaborative Group.
        Heart Rhythm. 2017; 14: 991-997
        • Santangeli P.
        • Zado E.S.
        • Supple G.E.
        • Haqqani H.M.
        • Garcia F.C.
        • Tschabrunn C.M.
        • Callans D.J.
        • Lin D.
        • Dixit S.
        • Hutchinson M.D.
        • Riley M.P.
        • Marchlinski F.E.
        Long-Term Outcome With Catheter Ablation of Ventricular Tachycardia in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy.
        Circ Arrhythm Electrophysiol. 2015; 8: 1413-1421
        • Mallidi J.
        • Nadkarni G.N.
        • Berger R.D.
        • Calkins H.
        • Nazarian S.
        Meta-analysis of catheter ablation as an adjunct to medical therapy for treatment of ventricular tachycardia in patients with structural heart disease.
        Heart Rhythm. 2011; 8: 503-510
        • Philips B.
        • te Riele A.S.
        • Sawant A.
        • Kareddy V.
        • James C.A.
        • Murray B.
        • Tichnell C.
        • Kassamali B.
        • Nazarian S.
        • Judge D.P.
        • Calkins H.
        • Tandri H.
        Outcomes and ventricular tachycardia recurrence characteristics after epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy.
        Heart Rhythm. 2015; 12: 716-725
        • Bai R.
        • Di Biase L.
        • Shivkumar K.
        • et al.
        Ablation of ventricular arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy: arrhythmia-free survival after endo-epicardial substrate based mapping and ablation.
        Circ Arrhythm Electrophysiol. 2011; 4: 478-485
        • Berruezo A.
        • Acosta J.
        • Fernandez-Armenta J.
        • et al.
        Safety, long-term outcomes and predictors of recurrence after first-line combined endoepicardial ventricular tachycardia substrate ablation in arrhythmogenic cardiomyopathy. Impact of arrhythmic substrate distribution pattern. A prospective multicentre study.
        Europace. 2017; 19: 607-616
        • Dalal D.
        • Jain R.
        • Tandri H.
        • et al.
        Long-term efficacy of catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy.
        J Am Coll Cardiol. 2007; 50: 432-440
        • Garcia F.C.
        • Bazan V.
        • Zado E.S.
        • Ren J.F.
        • Marchlinski F.E.
        Epicardial substrate and outcome with epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy/dysplasia.
        Circulation. 2009; 120: 366-375
        • Saberniak J.
        • Hasselberg N.E.
        • Borgquist R.
        • Platonov P.G.
        • Sarvari S.I.
        • Smith H.J.
        • Ribe M.
        • Holst A.G.
        • Edvardsen T.
        • Haugaa K.H.
        Vigorous physical activity impairs myocardial function in patients with arrhythmogenic right ventricular cardiomyopathy and in mutation positive family members.
        Eur J Heart Fail. 2014; 16: 1337-1344
        • James C.A.
        • Bhonsale A.
        • Tichnell C.
        • Murray B.
        • Russell S.D.
        • Tandri H.
        • Tedford R.J.
        • Judge D.P.
        • Calkins H.
        Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers.
        J Am Coll Cardiol. 2013; 62: 1290-1297
        • Te Riele A.
        • James C.A.
        • Sawant A.C.
        • et al.
        Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy in the Pediatric Population: Clinical Characterization and Comparison With Adult-Onset Disease.
        JACC Clin Electrophysiol. 2015; 1: 551-560
        • Sawant A.C.
        • Te Riele A.S.
        • Tichnell C.
        • Murray B.
        • Bhonsale A.
        • Tandri H.
        • Judge D.P.
        • Calkins H.
        • James C.A.
        Safety of American Heart Association-recommended minimum exercise for desmosomal mutation carriers.
        Heart Rhythm. 2016; 13: 199-207
        • Ruwald A.C.
        • Marcus F.
        • Estes 3rd, N.A.
        • Link M.
        • McNitt S.
        • Polonsky B.
        • Calkins H.
        • Towbin J.A.
        • Moss A.J.
        • Zareba W.
        Association of competitive and recreational sport participation with cardiac events in patients with arrhythmogenic right ventricular cardiomyopathy: results from the North American multidisciplinary study of arrhythmogenic right ventricular cardiomyopathy.
        Eur Heart J. 2015; 36: 1735-1743
        • Sen-Chowdhry S.
        • Syrris P.
        • Ward D.
        • Asimaki A.
        • Sevdalis E.
        • McKenna W.J.
        Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression.
        Circulation. 2007; 115: 1710-1720
        • Ainsworth B.E.
        • Haskell W.L.
        • Herrmann S.D.
        • Meckes N.
        • Bassett Jr., D.R.
        • Tudor-Locke C.
        • Greer J.L.
        • Vezina J.
        • Whitt-Glover M.C.
        • Leon A.S.
        2011 Compendium of Physical Activities: a second update of codes and MET values.
        Med Sci Sports Exerc. 2011; 43: 1575-1581
        • Strath S.J.
        • Kaminsky L.A.
        • Ainsworth B.E.
        • Ekelund U.
        • Freedson P.S.
        • Gary R.A.
        • Richardson C.R.
        • Smith D.T.
        • Swartz A.M.
        Guide to the assessment of physical activity: Clinical and research applications: a scientific statement from the American Heart Association.
        Circulation. 2013; 128: 2259-2279
        • Lie O.H.
        • Dejgaard L.A.
        • Saberniak J.
        • Rootwelt C.
        • Stokke M.K.
        • Edvardsen T.
        • Haugaa K.H.
        Harmful Effects of Exercise Intensity and Exercise Duration in Patients With Arrhythmogenic Cardiomyopathy.
        JACC Clin Electrophysiol. 2018; 4: 744-753
        • Reisinger J.
        • Dubrey S.W.
        • Lavalley M.
        • Skinner M.
        • Falk R.H.
        Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement.
        J Am Coll Cardiol. 1997; 30: 1046-1051
        • Eriksson A.
        • Eriksson P.
        • Olofsson B.O.
        • Thornell L.E.
        The sinoatrial node in familial amyloidosis with polyneuropathy. A clinico-pathological study of nine cases from northern Sweden.
        Virchows Arch A Pathol Anat Histopathol. 1984; 402: 239-246
        • Eriksson P.
        • Olofsson B.O.
        Pacemaker treatment in familial amyloidosis with polyneuropathy.
        Pacing Clin Electrophysiol. 1984; 7: 702-706
        • Sayed R.H.
        • Rogers D.
        • Khan F.
        • Wechalekar A.D.
        • Lachmann H.J.
        • Fontana M.
        • Mahmood S.
        • Sachchithanantham S.
        • Patel K.
        • Hawkins P.N.
        • Whelan C.J.
        • Gillmore J.D.
        A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis.
        Eur Heart J. 2015; 36: 1098-1105
        • Muchtar E.
        • Gertz M.A.
        • Kumar S.K.
        • et al.
        Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?.
        Amyloid. 2018; 25: 86-92
        • Rezk T.
        • Whelan C.J.
        • Lachmann H.J.
        • et al.
        Role of implantable intracardiac defibrillators in patients with cardiac immunoglobulin light chain amyloidosis.
        Br J Haematol. 2018; 182: 145-148
        • Tan N.Y.
        • Mohsin Y.
        • Hodge D.O.
        • Lacy M.Q.
        • Packer D.L.
        • Dispenzieri A.
        • Grogan M.
        • Asirvatham S.J.
        • Madhavan M.
        • Mc L.C.
        Catheter Ablation for Atrial Arrhythmias in Patients With Cardiac Amyloidosis.
        J Cardiovasc Electrophysiol. 2016; 27: 1167-1173
        • Hoedemaekers Y.M.
        • Caliskan K.
        • Michels M.
        • Frohn-Mulder I.
        • van der Smagt J.J.
        • Phefferkorn J.E.
        • Wessels M.W.
        • ten Cate F.J.
        • Sijbrands E.J.
        • Dooijes D.
        • Majoor-Krakauer D.F.
        The importance of genetic counseling, DNA diagnostics, and cardiologic family screening in left ventricular noncompaction cardiomyopathy.
        Circ Cardiovasc Genet. 2010; 3: 232-239
        • Muser D.
        • Liang J.J.
        • Witschey W.R.
        • et al.
        Ventricular arrhythmias associated with left ventricular noncompaction: Electrophysiologic characteristics, mapping, and ablation.
        Heart Rhythm. 2017; 14: 166-175
        • Miller E.M.
        • Hinton R.B.
        • Czosek R.
        • Lorts A.
        • Parrott A.
        • Shikany A.R.
        • Ittenbach R.F.
        • Ware S.M.
        Genetic Testing in Pediatric Left Ventricular Noncompaction.
        Circ Cardiovasc Genet. 2017; 10
        • Caliskan K.
        • Szili-Torok T.
        • Theuns D.A.
        • Kardos A.
        • Geleijnse M.L.
        • Balk A.H.
        • van Domburg R.T.
        • Jordaens L.
        • Simoons M.L.
        Indications and outcome of implantable cardioverter-defibrillators for primary and secondary prophylaxis in patients with noncompaction cardiomyopathy.
        J Cardiovasc Electrophysiol. 2011; 22: 898-904
        • Stollberger C.
        • Blazek G.
        • Dobias C.
        • Hanafin A.
        • Wegner C.
        • Finsterer J.
        Frequency of stroke and embolism in left ventricular hypertrabeculation/noncompaction.
        Am J Cardiol. 2011; 108: 1021-1023
        • Brescia S.T.
        • Rossano J.W.
        • Pignatelli R.
        • Jefferies J.L.
        • Price J.F.
        • Decker J.A.
        • Denfield S.W.
        • Dreyer W.J.
        • Smith O.
        • Towbin J.A.
        • Kim J.J.
        Mortality and sudden death in pediatric left ventricular noncompaction in a tertiary referral center.
        Circulation. 2013; 127: 2202-2208
        • Kohli S.K.
        • Pantazis A.A.
        • Shah J.S.
        • Adeyemi B.
        • Jackson G.
        • McKenna W.J.
        • Sharma S.
        • Elliott P.M.
        Diagnosis of left-ventricular non-compaction in patients with left-ventricular systolic dysfunction: time for a reappraisal of diagnostic criteria?.
        Eur Heart J. 2008; 29: 89-95
        • Gleva M.J.
        • Wang Y.
        • Curtis J.P.
        • Berul C.I.
        • Huddleston C.B.
        • Poole J.E.
        Complications Associated With Implantable Cardioverter Defibrillators in Adults With Congenital Heart Disease or Left Ventricular Noncompaction Cardiomyopathy (From the NCDR((R)) Implantable Cardioverter-Defibrillator Registry).
        Am J Cardiol. 2017; 120: 1891-1898
        • Gati S.
        • Papadakis M.
        • Papamichael N.D.
        • Zaidi A.
        • Sheikh N.
        • Reed M.
        • Sharma R.
        • Thilaganathan B.
        • Sharma S.
        Reversible de novo left ventricular trabeculations in pregnant women: implications for the diagnosis of left ventricular noncompaction in low-risk populations.
        Circulation. 2014; 130: 475-483
        • Andreini D.
        • Pontone G.
        • Bogaert J.
        • et al.
        Long-Term Prognostic Value of Cardiac Magnetic Resonance in Left Ventricle Noncompaction: A Prospective Multicenter Study.
        J Am Coll Cardiol. 2016; 68: 2166-2181
        • Ivanov A.
        • Dabiesingh D.S.
        • Bhumireddy G.P.
        • Mohamed A.
        • Asfour A.
        • Briggs W.M.
        • Ho J.
        • Khan S.A.
        • Grossman A.
        • Klem I.
        • Sacchi T.J.
        • Heitner J.F.
        Prevalence and Prognostic Significance of Left Ventricular Noncompaction in Patients Referred for Cardiac Magnetic Resonance Imaging.
        Circ Cardiovasc Imaging. 2017; 10
        • Sidhu M.S.
        • Uthamalingam S.
        • Ahmed W.
        • Engel L.C.
        • Vorasettakarnkij Y.
        • Lee A.M.
        • Hoffmann U.
        • Brady T.
        • Abbara S.
        • Ghoshhajra B.B.
        Defining left ventricular noncompaction using cardiac computed tomography.
        J Thorac Imaging. 2014; 29: 60-66
        • Chin T.K.
        • Perloff J.K.
        • Williams R.G.
        • Jue K.
        • Mohrmann R.
        Isolated noncompaction of left ventricular myocardium. A study of eight cases.
        Circulation. 1990; 82: 507-513
        • Jenni R.
        • Oechslin E.
        • Schneider J.
        • Attenhofer Jost C.
        • Kaufmann P.A.
        Echocardiographic and pathoanatomical characteristics of isolated left ventricular non-compaction: a step towards classification as a distinct cardiomyopathy.
        Heart. 2001; 86: 666-671
        • Stollberger C.
        • Finsterer J.
        • Blazek G.
        Left ventricular hypertrabeculation/noncompaction and association with additional cardiac abnormalities and neuromuscular disorders.
        Am J Cardiol. 2002; 90: 899-902
        • Petersen S.E.
        • Selvanayagam J.B.
        • Wiesmann F.
        • Robson M.D.
        • Francis J.M.
        • Anderson R.H.
        • Watkins H.
        • Neubauer S.
        Left ventricular non-compaction: insights from cardiovascular magnetic resonance imaging.
        J Am Coll Cardiol. 2005; 46: 101-105
        • Thuny F.
        • Jacquier A.
        • Jop B.
        • Giorgi R.
        • Gaubert J.Y.
        • Bartoli J.M.
        • Moulin G.
        • Habib G.
        Assessment of left ventricular non-compaction in adults: side-by-side comparison of cardiac magnetic resonance imaging with echocardiography.
        Archives of cardiovascular diseases. 2010; 103: 150-159